[96a5a0]: / output / allTrials / identified / NCT01639001_identified.json

Download this file

639 lines (639 with data), 29.8 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
{
"info": {
"nct_id": "NCT01639001",
"official_title": "PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED EAST ASIAN PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS",
"inclusion_criteria": "* Histologically or cytologically proven diagnosis of locally advanced not suitable for local treatment, recurrent and metastatic non-squamous cell carcinoma of the lung.\n* Positive for translocation or inversion events involving the ALK gene locus.\n* No prior systemic treatment for locally advanced or metastatic disease. Patients with brain metastases only if treated and neurologically stable for at least 2 weeks and are not taking any medications contraindicated in Exclusion Criteria\n* Evidence of a personally signed and dated informed consent document and willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures including completion of patient reported outcome [PRO] measures.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
"exclusion_criteria": "* Current treatment on another therapeutic clinical trial.\n* Prior therapy directly targeting ALK.\n* Any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack. Appropriate treatment with anticoagulants is permitted.\n* Ongoing cardiac dysrhythmias of NCI CTCAE Grade >=2, uncontrolled atrial fibrillation of any grade, or QTc interval >470 msec.\n* Pregnancy or breastfeeding.\n* Use of drugs or foods that are known potent CYP3A inducers/inhibitors Concurrent use of drugs that are CYP3A substrates with narrow therapeutic indices.\n* Known HIV infection\n* History of extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not history of prior radiation pneumonitis.\n* Other severe acute or chronic medical conditions (including severe gastrointestinal conditions such as diarrhea or ulcer) or psychiatric conditions, or end-stage renal disease on hemodialysis, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, and which would, therefore, make the patient inappropriate for entry into this study.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Histologically or cytologically proven diagnosis of locally advanced not suitable for local treatment, recurrent and metastatic non-squamous cell carcinoma of the lung.",
"criterions": [
{
"exact_snippets": "Histologically or cytologically proven diagnosis",
"criterion": "diagnosis method",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "locally advanced not suitable for local treatment",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "locally advanced"
},
{
"requirement_type": "treatment suitability",
"expected_value": false
}
]
},
{
"exact_snippets": "recurrent",
"criterion": "cancer recurrence",
"requirements": [
{
"requirement_type": "recurrence",
"expected_value": true
}
]
},
{
"exact_snippets": "metastatic",
"criterion": "cancer metastasis",
"requirements": [
{
"requirement_type": "metastasis",
"expected_value": true
}
]
},
{
"exact_snippets": "non-squamous cell carcinoma of the lung",
"criterion": "cancer type",
"requirements": [
{
"requirement_type": "type",
"expected_value": "non-squamous cell carcinoma of the lung"
}
]
}
]
},
{
"line": "* Positive for translocation or inversion events involving the ALK gene locus.",
"criterions": [
{
"exact_snippets": "Positive for translocation or inversion events involving the ALK gene locus.",
"criterion": "ALK gene locus",
"requirements": [
{
"requirement_type": "translocation or inversion events",
"expected_value": "positive"
}
]
}
]
},
{
"line": "* No prior systemic treatment for locally advanced or metastatic disease. Patients with brain metastases only if treated and neurologically stable for at least 2 weeks and are not taking any medications contraindicated in Exclusion Criteria",
"criterions": [
{
"exact_snippets": "No prior systemic treatment for locally advanced or metastatic disease",
"criterion": "prior systemic treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "brain metastases only if treated and neurologically stable for at least 2 weeks",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": true
},
{
"requirement_type": "neurological stability",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "not taking any medications contraindicated in Exclusion Criteria",
"criterion": "medications contraindicated in Exclusion Criteria",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Evidence of a personally signed and dated informed consent document and willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures including completion of patient reported outcome [PRO] measures.",
"criterions": [
{
"exact_snippets": "Evidence of a personally signed and dated informed consent document",
"criterion": "informed consent document",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "willingness and ability to comply with scheduled visits",
"criterion": "compliance with scheduled visits",
"requirements": [
{
"requirement_type": "willingness and ability",
"expected_value": true
}
]
},
{
"exact_snippets": "willingness and ability to comply with ... treatment plans",
"criterion": "compliance with treatment plans",
"requirements": [
{
"requirement_type": "willingness and ability",
"expected_value": true
}
]
},
{
"exact_snippets": "willingness and ability to comply with ... laboratory tests",
"criterion": "compliance with laboratory tests",
"requirements": [
{
"requirement_type": "willingness and ability",
"expected_value": true
}
]
},
{
"exact_snippets": "willingness and ability to comply with ... other study procedures",
"criterion": "compliance with other study procedures",
"requirements": [
{
"requirement_type": "willingness and ability",
"expected_value": true
}
]
},
{
"exact_snippets": "willingness and ability to comply with ... completion of patient reported outcome [PRO] measures",
"criterion": "completion of patient reported outcome [PRO] measures",
"requirements": [
{
"requirement_type": "willingness and ability",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 70 Years",
"criterions": [
{
"exact_snippets": "maximum age of 70 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 70,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Current treatment on another therapeutic clinical trial.",
"criterions": [
{
"exact_snippets": "Current treatment on another therapeutic clinical trial.",
"criterion": "current treatment on another therapeutic clinical trial",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Prior therapy directly targeting ALK.",
"criterions": [
{
"exact_snippets": "Prior therapy directly targeting ALK",
"criterion": "prior therapy",
"requirements": [
{
"requirement_type": "target",
"expected_value": "ALK"
}
]
}
]
},
{
"line": "* Any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack. Appropriate treatment with anticoagulants is permitted.",
"criterions": [
{
"exact_snippets": "myocardial infarction ... within the 3 months prior to starting study treatment",
"criterion": "myocardial infarction",
"requirements": [
{
"requirement_type": "time since event",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 3,
"unit": "months"
}
]
}
}
]
},
{
"exact_snippets": "severe/unstable angina ... within the 3 months prior to starting study treatment",
"criterion": "severe/unstable angina",
"requirements": [
{
"requirement_type": "time since event",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 3,
"unit": "months"
}
]
}
}
]
},
{
"exact_snippets": "coronary/peripheral artery bypass graft ... within the 3 months prior to starting study treatment",
"criterion": "coronary/peripheral artery bypass graft",
"requirements": [
{
"requirement_type": "time since event",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 3,
"unit": "months"
}
]
}
}
]
},
{
"exact_snippets": "congestive heart failure ... within the 3 months prior to starting study treatment",
"criterion": "congestive heart failure",
"requirements": [
{
"requirement_type": "time since event",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 3,
"unit": "months"
}
]
}
}
]
},
{
"exact_snippets": "cerebrovascular accident including transient ischemic attack ... within the 3 months prior to starting study treatment",
"criterion": "cerebrovascular accident including transient ischemic attack",
"requirements": [
{
"requirement_type": "time since event",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 3,
"unit": "months"
}
]
}
}
]
}
]
},
{
"line": "* Ongoing cardiac dysrhythmias of NCI CTCAE Grade >=2, uncontrolled atrial fibrillation of any grade, or QTc interval >470 msec.",
"criterions": [
{
"exact_snippets": "Ongoing cardiac dysrhythmias of NCI CTCAE Grade >=2",
"criterion": "cardiac dysrhythmias",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "NCI CTCAE Grade"
}
}
]
},
{
"exact_snippets": "uncontrolled atrial fibrillation of any grade",
"criterion": "atrial fibrillation",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
}
]
},
{
"exact_snippets": "QTc interval >470 msec",
"criterion": "QTc interval",
"requirements": [
{
"requirement_type": "length",
"expected_value": {
"operator": ">",
"value": 470,
"unit": "msec"
}
}
]
}
]
},
{
"line": "* Pregnancy or breastfeeding.",
"criterions": [
{
"exact_snippets": "Pregnancy",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "breastfeeding",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Use of drugs or foods that are known potent CYP3A inducers/inhibitors Concurrent use of drugs that are CYP3A substrates with narrow therapeutic indices.",
"criterions": [
{
"exact_snippets": "Use of drugs or foods that are known potent CYP3A inducers/inhibitors",
"criterion": "use of CYP3A inducers/inhibitors",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Concurrent use of drugs that are CYP3A substrates with narrow therapeutic indices",
"criterion": "use of CYP3A substrates with narrow therapeutic indices",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Known HIV infection",
"criterions": [
{
"exact_snippets": "Known HIV infection",
"criterion": "HIV infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Other severe acute or chronic medical conditions (including severe gastrointestinal conditions such as diarrhea or ulcer) or psychiatric conditions, or end-stage renal disease on hemodialysis, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, and which would, therefore, make the patient inappropriate for entry into this study.",
"criterions": [
{
"exact_snippets": "severe acute or chronic medical conditions",
"criterion": "severe acute or chronic medical conditions",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "severe gastrointestinal conditions such as diarrhea or ulcer",
"criterion": "severe gastrointestinal conditions",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "psychiatric conditions",
"criterion": "psychiatric conditions",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "end-stage renal disease on hemodialysis",
"criterion": "end-stage renal disease on hemodialysis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "laboratory abnormalities",
"criterion": "laboratory abnormalities",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "* History of extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not history of prior radiation pneumonitis.",
"criterions": [
{
"exact_snippets": "History of extensive disseminated/bilateral ... interstitial fibrosis or interstitial lung disease",
"criterion": "extensive disseminated/bilateral interstitial fibrosis or interstitial lung disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease",
"criterion": "Grade 3 or 4 interstitial fibrosis or interstitial lung disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "history of pneumonitis",
"criterion": "pneumonitis",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "history of hypersensitivity pneumonitis",
"criterion": "hypersensitivity pneumonitis",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "history of interstitial pneumonia",
"criterion": "interstitial pneumonia",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "history of interstitial lung disease",
"criterion": "interstitial lung disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "history of obliterative bronchiolitis",
"criterion": "obliterative bronchiolitis",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "history of pulmonary fibrosis",
"criterion": "pulmonary fibrosis",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "not history of prior radiation pneumonitis",
"criterion": "prior radiation pneumonitis",
"requirements": [
{
"requirement_type": "history",
"expected_value": false
}
]
}
]
}
],
"failed_miscellaneous": []
}